{"id":"https://openalex.org/W3032064298","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.3006","title":"Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial.","display_name":"Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial.","publication_year":2020,"publication_date":"2020-05-20","ids":{"openalex":"https://openalex.org/W3032064298","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.3006","mag":"3032064298"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2020.38.15_suppl.3006","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.3006","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.3006","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043463827","display_name":"Fran\u00e7ois Ghiringhelli","orcid":"https://orcid.org/0000-0002-5465-8305","observed_orcids":["https://orcid.org/0000-0002-5465-8305"]},"institutions":[{"id":"https://openalex.org/I4210094685","display_name":"Centre Georges Fran\u00e7ois Leclerc","ror":"https://ror.org/00pjqzf38","country_code":"FR","type":"facility","lineage":["https://openalex.org/I4210094685","https://openalex.org/I4210141925"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Fran\u00e7ois Ghiringhelli","raw_affiliation_strings":["Department of Medical Oncology, Center GF Leclerc, Dijon, France, Dijon, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Center GF Leclerc, Dijon, France, Dijon, France;","institution_ids":["https://openalex.org/I4210094685"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013525685","display_name":"Benoist Chibaudel","orcid":"https://orcid.org/0000-0003-1279-2044","observed_orcids":["https://orcid.org/0000-0003-1279-2044"]},"institutions":[{"id":"https://openalex.org/I4210123797","display_name":"GERCOR (France)","ror":"https://ror.org/024w4dn76","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210123797"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Benoist Chibaudel","raw_affiliation_strings":["GERCOR, Paris, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GERCOR, Paris, France;","institution_ids":["https://openalex.org/I4210123797"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024180743","display_name":"Julien Ta\u00efeb","orcid":"https://orcid.org/0000-0002-9955-4753","observed_orcids":["https://orcid.org/0000-0002-9955-4753"]},"institutions":[{"id":"https://openalex.org/I4210102325","display_name":"H\u00f4pital Europ\u00e9en Georges-Pompidou","ror":"https://ror.org/016vx5156","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210102325","https://openalex.org/I4210120235"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Julien Taieb","raw_affiliation_strings":["H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H\u00f4pital Europ\u00e9en Georges Pompidou, Paris, France;","institution_ids":["https://openalex.org/I4210102325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030078141","display_name":"Jaafar Bennouna","orcid":"https://orcid.org/0000-0002-5034-1108","observed_orcids":["https://orcid.org/0000-0002-5034-1108"]},"institutions":[{"id":"https://openalex.org/I3019204325","display_name":"Centre Hospitalier Universitaire de Nantes","ror":"https://ror.org/05c1qsg97","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019204325"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jaafar Bennouna","raw_affiliation_strings":["University Hospital of Nantes, Digestive Oncology, Nantes, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital of Nantes, Digestive Oncology, Nantes, France;","institution_ids":["https://openalex.org/I3019204325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078279528","display_name":"J\u00e9r\u00f4me Martin-Babau","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210132604","display_name":"Centre Hospitalier R\u00e9gional Universitaire de Brest","ror":"https://ror.org/03evbwn87","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I154526488","https://openalex.org/I4210105774","https://openalex.org/I4210132604","https://openalex.org/I4210161065"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jerome Martin-Babau","raw_affiliation_strings":["Medical Oncology, C.H.U Augustin Morvan-Brest University Hospital, Brest, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, C.H.U Augustin Morvan-Brest University Hospital, Brest, France;","institution_ids":["https://openalex.org/I4210132604"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018037138","display_name":"Marianne Fonck","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134409","display_name":"Institut Bergoni\u00e9","ror":"https://ror.org/02yw1f353","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210134409"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Marianne Fonck","raw_affiliation_strings":["Institut Bergoni\u00e9, CLCC Bordeaux, Bordeaux, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Bergoni\u00e9, CLCC Bordeaux, Bordeaux, France;","institution_ids":["https://openalex.org/I4210134409"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022288769","display_name":"Christophe Borg","orcid":"https://orcid.org/0000-0002-2167-1458","observed_orcids":["https://orcid.org/0000-0002-2167-1458","https://orcid.org/0000-0001-6161-0169"]},"institutions":[{"id":"https://openalex.org/I4210087978","display_name":"Centre Hospitalier Universitaire de Besan\u00e7on","ror":"https://ror.org/0084te143","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210087978"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Christophe Borg","raw_affiliation_strings":["CHRU Jean Minjoz, UMR1098, Besan\u00e7on, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CHRU Jean Minjoz, UMR1098, Besan\u00e7on, France;","institution_ids":["https://openalex.org/I4210087978"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049661683","display_name":"Romain Cohen","orcid":"https://orcid.org/0000-0001-9602-5162","observed_orcids":["https://orcid.org/0000-0001-9602-5162"]},"institutions":[{"id":"https://openalex.org/I39804081","display_name":"Sorbonne Universit\u00e9","ror":"https://ror.org/02en5vm52","country_code":"FR","type":"education","lineage":["https://openalex.org/I39804081"]},{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Romain Cohen","raw_affiliation_strings":["Sorbonne University, Department of Medical Oncology, Saint-Antoine, AP-HP, F-75012, Paris, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sorbonne University, Department of Medical Oncology, Saint-Antoine, AP-HP, F-75012, Paris, France;","institution_ids":["https://openalex.org/I39804081","https://openalex.org/I4210097159"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085250039","display_name":"Marion Thibaudin","orcid":"https://orcid.org/0000-0002-1046-5982","observed_orcids":["https://orcid.org/0000-0002-1046-5982"]},"institutions":[{"id":"https://openalex.org/I4210094685","display_name":"Centre Georges Fran\u00e7ois Leclerc","ror":"https://ror.org/00pjqzf38","country_code":"FR","type":"facility","lineage":["https://openalex.org/I4210094685","https://openalex.org/I4210141925"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Marion Thibaudin","raw_affiliation_strings":["Center GF Leclerc, Dijon, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center GF Leclerc, Dijon, France;","institution_ids":["https://openalex.org/I4210094685"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018585640","display_name":"Emeric Limagne","orcid":"https://orcid.org/0000-0002-1098-8441","observed_orcids":["https://orcid.org/0000-0002-1098-8441"]},"institutions":[{"id":"https://openalex.org/I4210094685","display_name":"Centre Georges Fran\u00e7ois Leclerc","ror":"https://ror.org/00pjqzf38","country_code":"FR","type":"facility","lineage":["https://openalex.org/I4210094685","https://openalex.org/I4210141925"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Emeric Limagne","raw_affiliation_strings":["Centre Georges Fran\u00e7ois Leclerc, Dijon, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre Georges Fran\u00e7ois Leclerc, Dijon, France;","institution_ids":["https://openalex.org/I4210094685"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5016814827","display_name":"Jean-David Fumet","orcid":"https://orcid.org/0000-0002-9444-941X","observed_orcids":["https://orcid.org/0000-0002-9444-941X"]},"institutions":[{"id":"https://openalex.org/I4210094685","display_name":"Centre Georges Fran\u00e7ois Leclerc","ror":"https://ror.org/00pjqzf38","country_code":"FR","type":"facility","lineage":["https://openalex.org/I4210094685","https://openalex.org/I4210141925"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jean-David Fumet","raw_affiliation_strings":["CGFL, Dijon, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CGFL, Dijon, France;","institution_ids":["https://openalex.org/I4210094685"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":41,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"38","issue":"15_suppl","first_page":"3006","last_page":"3006"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8593999743461609,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8593999743461609,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.13850000500679016,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10335","display_name":"Colorectal Cancer Surgical Treatments","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/durvalumab","display_name":"durvalumab","score":0.9959999918937683},{"id":"https://openalex.org/keywords/tremelimumab","display_name":"tremelimumab","score":1.0},{"id":"https://openalex.org/keywords/folfox","display_name":"FOLFOX","score":0.9129999876022339},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.8899999856948853},{"id":"https://openalex.org/keywords/ras-mutations","display_name":"RAS mutations","score":0.8840000033378601},{"id":"https://openalex.org/keywords/microsatellite-stability","display_name":"microsatellite stable","score":0.8050000071525574},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.7889999747276306},{"id":"https://openalex.org/keywords/anti-ctla-4","display_name":"anti-CTLA-4","score":0.9890000224113464},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7509999871253967},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.625},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.753000020980835},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6660000085830688},{"id":"https://openalex.org/keywords/immunotherapy-safety","display_name":"immunotherapy safety","score":0.5860000252723694},{"id":"https://openalex.org/keywords/immunogenic-cell-death","display_name":"immunogenic cell death","score":0.7519999742507935},{"id":"https://openalex.org/keywords/myeloid-derived-suppressor-cells","display_name":"myeloid-derived suppressor cells","score":0.9470000267028809}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8951146602630615},{"id":"https://openalex.org/C2778260052","wikidata":"https://www.wikidata.org/wiki/Q117636","display_name":"FOLFOX","level":5,"score":0.6631376147270203},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6615631580352783},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.6131747961044312},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5838455557823181},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.5778529644012451},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5625482797622681},{"id":"https://openalex.org/C2778650287","wikidata":"https://www.wikidata.org/wiki/Q7838098","display_name":"Tremelimumab","level":5,"score":0.5475186705589294},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5455417633056641},{"id":"https://openalex.org/C2777742743","wikidata":"https://www.wikidata.org/wiki/Q19904005","display_name":"Durvalumab","level":5,"score":0.51056969165802},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.4723295569419861},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.4636918306350708},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.46210750937461853},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.42424774169921875},{"id":"https://openalex.org/C2780873365","wikidata":"https://www.wikidata.org/wiki/Q496812","display_name":"Leukopenia","level":3,"score":0.41627562046051025},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.4110153019428253},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3238658905029297},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.29950442910194397},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.29123711585998535},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.21741393208503723},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.20081132650375366},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.1891435980796814},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.1542932093143463}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2020.38.15_suppl.3006","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.3006","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.3006","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3202040873","https://openalex.org/W4385737353","https://openalex.org/W2905294510","https://openalex.org/W4393988641","https://openalex.org/W2809595917","https://openalex.org/W3213549074","https://openalex.org/W4293239387","https://openalex.org/W4406892034","https://openalex.org/W3004537286","https://openalex.org/W4400933413"],"abstract_inverted_index":{"3006":[0],"Background:":[1],"Single":[2],"agent":[3],"PD-1/L1":[4],"inhibition":[5],"are":[6,93,109],"not":[7,245],"effective":[8],"in":[9,32,79,255,290],"metastatic":[10],"colorectal":[11],"cancer":[12],"(MCRC)":[13],"with":[14,81,95,153],"microsatellite":[15],"stable":[16],"tumors.":[17],"However,":[18],"signal":[19],"of":[20,27,44,90,141,143,170,175,178,214,286,301],"efficacy":[21,126,163,285],"was":[22,129,165,244,253],"shown":[23],"using":[24],"combo":[25],"therapy":[26],"anti-PD-L1":[28],"and":[29,42,84,113,118,151,192,208,234,264,284],"anti":[30],"CTLA-4":[31],"multitreated":[33],"patients.":[34],"FOLFOX":[35],"regimen":[36,156,289],"could":[37],"induced":[38],"immunogenic":[39],"cell":[40],"death":[41],"elimination":[43],"myeloid":[45],"derived":[46],"suppressor":[47],"cells":[48],"(MDSCs)":[49],"thus":[50],"leading":[51],"to":[52,71,75,219,240],"a":[53,64,173],"potential":[54],"positive":[55],"effect":[56],"on":[57,167],"antitumor":[58],"immune":[59,120],"response.":[60],"Methods:":[61],"This":[62],"is":[63,101],"single":[65],"arm":[66],"exploratory":[67],"investigator-initiated":[68],"trial":[69,305],"planned":[70,130],"include":[72,201],"57":[73],"pts":[74,148,257],"receive":[76],"mFOLFOX6":[77],"(6cycles)":[78],"combination":[80],"durvalumab":[82,96],"(150mg/q2W)":[83],"tremelimumab":[85],"(75mg/q4W).":[86],"After":[87],"6":[88,102,137,251],"cycles":[89],"chemotherapy,":[91],"patients":[92],"treated":[94,152],"untils":[97],"progression.":[98],"Primary":[99],"endpoint":[100],"months\u2019":[103],"progression-free":[104],"survival":[105,249],"rate.":[106],"Secondary":[107],"endpoints":[108],"response":[110],"rate,":[111],"tolerability":[112],"translational":[114,268],"research":[115],"evaluating":[116],"tissue":[117],"blood":[119,210],"parameter.":[121],"Upon":[122],"Simon\u2019s":[123],"design":[124],"an":[125],"intermediate":[127,162],"analysis":[128,164,280],"after":[131,172,299],"the":[132,146,154,168,274,287],"16th":[133],"patient":[134],"has":[135,222,281],"passed":[136],"months.":[138],"Results:":[139],"As":[140],"1st":[142,169],"January":[144,171],"2020":[145],"55/57":[147],"were":[149,184,217],"enrolled":[150],"MEDETREME":[155],"at":[157,250,273],"8":[158],"French":[159],"sites.":[160],"The":[161,180,277],"conducted":[166],"median":[174],"13.4":[176],"months":[177,252],"treatment.":[179],"following":[181],"adverse":[182,215],"events":[183,216],"noted:":[185],"asthenia":[186,202],"(81.25%),":[187],"neuropathy":[188],"(87.5%),":[189],"diarrhea":[190,204],"(56.25%)":[191],"neutropenia":[193,206],"(62.5%).":[194],"Notable":[195],"grade":[196,227,232,237],"3/4":[197],"(CTC":[198],"AE":[199],"4.03)":[200],"(18.75%)":[203],"(12.5%)":[205],"(50%)":[207],"elevated":[209],"pressure":[211],"(25%).":[212],"Most":[213],"related":[218,239],"chemotherapy.":[220],"It":[221],"been":[223],"noted":[224],"one":[225,229,235],"cytolysis":[226],"3,":[228],"thyroid":[230],"dysfunction":[231],"3":[233,238],"hypophysitis":[236],"immunotherapy.":[241],"Median":[242],"PFS":[243],"reached.":[246],"Progression":[247],"free":[248],"observed":[254],"10/16":[256],"(62,5%)":[258],"given":[259],"5":[260,262],"CR,":[261],"PR":[263],"4":[265],"SD.":[266],"Updated":[267],"data":[269],"will":[270,296],"be":[271,297],"presented":[272,298],"meeting.":[275],"Conclusions:":[276],"interim":[278],"safety":[279,283],"supported":[282],"MEDITREME":[288],"first-":[291],"line":[292],"MCRC.":[293],"Finally,":[294],"results":[295],"maturation":[300],"follow":[302],"up.":[303],"Clinical":[304],"information:":[306],"NCT03202758":[307],".":[308]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":12},{"year":2020,"cited_by_count":4}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2020-06-05T00:00:00"}